Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment

• DOI: 10.1093/nop/npz008
• Publication Date: 2019-04-22T08:13:10Z
• Authors: Emma van Kessel; Michelle A C Emons; Irene H Wajer; Kirsten M van Baa...; Marike L Broekman; Pierre A Robe; Tom J Snijders; Martine J E Van Z...
• Keywords: Neurocognitive

Impairments in neurocognitive functioning (NCF) frequently occur glioma patients. Both the tumor and its treatment contribute to these impairments. We aimed quantify NCF patients before investigate which factors influence NCF.We performed a retrospective cohort study diffuse according STROBE (Strengthening Reporting of Observational Studies Epidemiology) criteria. All had undergone neuropsychological assessment as part routine clinical care, awake surgery. studied "overall NCF" 5 domains separately. For per domain, we analyses at 2 different levels outcome measures: (1) group level: mean cognitive sample, (2) individual percentage impaired multivariable logistic regression were associated with occurrence impairments.From our (2010-2016), 168 met all inclusion significantly affected level. The percentages impairments (-2SD) highest for Executive Functioning, Psychomotor Speed, Memory (26.5%, 23.2%, 19.3%, respectively). Patients high-grade more severely than low-grade glioma. Tumor volume, isocitrate dehydrogenase status, WHO grade, histology domain-specific impairments.Cognitive impairment occurs majority treatment-naive are involved most frequently. These explained not only by location but also other (biological) mechanisms.